Webinar
Identifying HER2-low expression – A pathologist led slide review
On-demand
As our understanding of breast cancer grows, our portfolio of sensitive and clinically actionable solutions evolve.
Since 1991 Roche has battled cancer with innovation to push standards of care forward. More than ever identifying each level of HER2 expression is critical for clinical decision making.
Roche Tissue Diagnostics invites you to learn more about the importance of identifying each level of HER2 expression to include HER2-low for whom ENHERTU® may be considered.
Webinar Learning Objectives:
- Review the new HER2-low category of tumor expression
- Perform an image review and discuss scoring for select cases
- Perform an image review and discuss scoring for difficult cases
- Live Question & Answer
Jim Richter
Dr. Jim Richter, MD, is a Pathology Liaison in Medical and Scientific Affairs (MSA) at Roche Diagnostics, where he works as a consultant for internal and external colleagues. His emphasis is to help stakeholders better understand the landscape of precision therapeutics and companion diagnostics to improve patient outcomes.